SXTP
60 Degrees Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
−1.16%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
Market Cap
$3.23M
MomentumView details →
1D Return
−1.16%
YTD Return
−53.85%
RSI (14)
30.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
Market Cap
$3.23M
RSI (14)
30.4
MomentumView details →
1D Return
−1.16%
YTD Return
−53.85%
SummaryUpdated Jun 1, 2026
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is a specialty pharmaceutical company founded in 2010 and headquartered in Washington, D.C. The company went public in July 2023 and focuses on developing and commercializing therapies for the prevention and treatment of infectious diseases. Since its IPO, the company has experienced significant stock price volatility, declining from over $16 per share in 2023 to around $2 per share currently, reflecting the challenges typical of early-stage biotech companies with limited commercial revenue.
Similar companies
Latest newsMore news →
60 Degrees Pharmaceuticals reported its financial results for the second quarter of 2026, with net product revenues increasing approximately 106% to about $208 thousand from about $101 thousand in the same quarter of 2025.21d ago60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.32d ago